Accelerated Coasting Does Not Affect Oocyte Maturation.

AIMS: The study aimed to assess the efficacy of accelerating the process of coasting through adding gonadotropin releasing hormone (GnRH) antagonist (GnRH-ant) on the day of triggering of oocyte maturation without withholding the GnRH agonist (GnRHa) in women at risk for developing ovarian hyperstimulation syndrome (OHSS). METHODS: Retrospective case-control study of the outcomes of GnRHa cycles in which women were at risk to develop OHSS. Women who underwent acceleration of coasting (n = 50) were compared with a control group of women who underwent usual coasting (n = 57). RESULTS: The oocyte maturation and fertilization rates were significantly higher in the accelerated coasting group than in the usual coasting group (83.05 vs. 67.62%; p < 0.001 and 79.85 vs. 65.84%; p < 0.001, respectively). The pregnancy rates were higher in the accelerated coasting group than in the usual coasting group but without statistically significant difference. The incidences of mild, moderate, and severe OHSS were not significantly different between both groups. CONCLUSION: Acceleration of coasting in cases of OHSS through treatment with GnRH-ant after pituitary suppression with GnRHa offered a novel approach to reduce estradiol level, avoid cycle cancellation, and maintain excellent oocyte maturation rate and thus high pregnancy rate with prevention of OHSS.

Study of Breast Cancer Resistance Protein ABCG2 C421A Single Nucleotide Polymorphism RS2231142 in Multiple Myeloma.

Breast cancer resistance protein is an adenosine triphosphate-binding cassette (ABC) transporter that belongs to the G-superfamily. It acts as an efflux pump that is crucial for cell protection against toxic compounds and xenobiotics such as procarcinogens. An individual's risk of developing carcinoma depends on genetic variations like single nucleotide polymorphisms (SNPs) that may cause alteration in gene expression and/or reductions in their activities. These changes may influence blood cells' exposure to toxic compounds and increase the susceptibility to multiple myeloma (MM). Our study aimed at investigating polymorphisms at position C421A of the ABCG-2 gene in MM for the first time in Egyptian patients. Peripheral blood mononuclear cells were analyzed for ABCG-2-C421A gene polymorphisms using real-time quantitative polymerase chain reaction in 50 MM patients and 50 control subjects. There is a statistically significant correlation between SNP-C421A of the ABCG-2 gene and the risk for MM (p = 0.0218). Preliminary studies suggest that SNP-C421A of the ABCG-2 gene can be helpful in predicting the risk of developing MM. Supplementary Information: The online version contains supplementary material available at 10.1007/s12288-022-01523-3.